US announces support of COVID-19 vaccine IP waiver, though WTO negotiations likely to take months. Our experts weig… https://t.co/A09BhLWtWz
Impact of passing through rebates at the POS for diabetes medicines
Diabetes imposes a significant economic burden on Medicare, at a cost of more than $100 billion annually. Adherence to prescription medicines to treat diabetes is associated with better disease management and lower overall health care spending, yet high beneficiary out-of-pocket (OOP) costs are a common barrier to proper adherence. Passing through a share of negotiated manufacturer rebates to patients at the point of sale (POS) is a recently debated approach to lower patient OOP costs, but little attention has been paid to its potential to improve adherence and generate downstream savings.
To fill this critical data gap, we modeled the effects of passing through rebates at POS on Medicare Parts A and B spending as a result of improved adherence. This is the first research to quantify these effects. We estimate that for each beneficiary using brand diabetes medicines in the Part D coverage gap or catastrophic phase, passing through a portion of rebates at the POS would reduce overall per beneficiary healthcare spending by $1,352 and lower patient OOP spending by $367 in one year. Over the next 10 years, we project that passing through rebates at the POS for diabetes medicines could reduce total medical spending by approximately $20 billion. These findings highlight the capability of passing through rebates to not only improve access to recommended medicines, but also to improve health outcomes and reduce overall healthcare spending.
These results suggest that the adherence improvements resulting from passing through a portion of rebates could generate substantial savings across the entire Medicare program.
Additional details are available in the complete report. This research is supported by funding from Pharmaceutical Research and Manufacturers of America (PhRMA).
- US announces support of COVID-19 vaccine IP waiver
- Why are pharma prices changing?
- Supply chain resilience and the cost to pharmaceutical trade
- Japan’s new CEA-based price adjustments set to maintain pricing pressure on innovative drugs
- Vaccine hesitancy boosts risks from vaccine nationalism
- The risks of vaccine nationalism
- Unlocking biomarker diagnostics in Europe and the win-win for the innovative oncology sector
- Biden administration scores first legislative win for pharmaceutical pricing reform
We use our inhouse data and visualization tool to understand the reasons behind medicines price changes. here is h… https://t.co/C5jgbZXHAV
As governments look to accelerate efforts to onshore production of essential products due to the COVID-19 pandemic,… https://t.co/50dJgGycL3